Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (17)

Jul 1, 2036formulationUS 10167291
Jul 1, 2036compositionUS 11059829
Jul 1, 2036compositionUS 9796721
Aug 11, 2035method-of-use (U-4431)US 11166951
Aug 11, 2035method-of-use (U-4427)US 11166951
Jan 21, 2035method-of-use (U-4109)US 10272083
Jan 21, 2035method-of-use (U-2687)US 10272083
Jan 21, 2035method-of-use (U-3710)US 11771696
Jan 21, 2035method-of-use (U-3710)US 11771696
Jul 11, 2032method-of-use (U-2668)US 10239883
Jul 11, 2032method-of-use (U-2666)US 10239883
Jul 11, 2032compositionUS 9290504
Jul 11, 2032compositionUS 9290504
Jul 11, 2032method-of-use (U-2145)US 9758524
Jul 11, 2032method-of-use (U-2145)US 9758524
Nov 24, 2026compositionUS 745955496d
Nov 24, 2026compositionUS 745955496d

FDA exclusivities (3)

Jan 16, 2028I-960Indication (3y)1.4y
Jan 16, 2028I-960Indication (3y)1.4y
Nov 21, 2026ODE-274Orphan Drug (7y)93d

News(1)

Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
onclive · 3mo ago

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

CALQUENCE

Marketedupdated 3mo ago

by $AZN ASTRAZENECA PLC🔗 ChEMBL

Approved

community read0 votes

🐶 often sniffed alongside

top 7

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 20 investigational indications.

indications

investigational

DLBCL

targets

Tyrosine-protein kinase BTK

all catalysts(13)

approval · 12

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval

CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval

CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE (ACALABRUTINIB MALEATE) — FDA approval

CALQUENCE (ACALABRUTINIB) — FDA approval

CALQUENCE

→

phase 1 2 completion · 1

AstraZeneca Plc — Calquence (Phase I/II Trial Completion)

CALQUENCE

→

view all 13 catalysts →

Trials studying CALQUENCE

phase4Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failurerecruitingn=60
phase3A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)recruitingn=1,200
phase2Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumabrecruitingn=80
phase2An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphomaactive not recruitingn=124
phase3A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLactive not recruitingn=310
phase2Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomarecruitingn=168
phase2A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphomaactive not recruitingn=108
phase2ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemiaactive not recruitingn=306

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 21, 2026

93 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (17)

Jul 1, 2036formulationUS 10167291
Jul 1, 2036compositionUS 11059829
Jul 1, 2036compositionUS 9796721
Aug 11, 2035method-of-use (U-4431)US 11166951
Aug 11, 2035method-of-use (U-4427)US 11166951
Jan 21, 2035method-of-use (U-4109)US 10272083
Jan 21, 2035method-of-use (U-2687)US 10272083
Jan 21, 2035method-of-use (U-3710)US 11771696
Jan 21, 2035method-of-use (U-3710)US 11771696
Jul 11, 2032method-of-use (U-2668)US 10239883
Jul 11, 2032method-of-use (U-2666)US 10239883
Jul 11, 2032compositionUS 9290504
Jul 11, 2032compositionUS 9290504
Jul 11, 2032method-of-use (U-2145)US 9758524
Jul 11, 2032method-of-use (U-2145)US 9758524
Nov 24, 2026compositionUS 745955496d
Nov 24, 2026compositionUS 745955496d

FDA exclusivities (3)

Jan 16, 2028I-960Indication (3y)1.4y
Jan 16, 2028I-960Indication (3y)1.4y
Nov 21, 2026ODE-274Orphan Drug (7y)93d

News(1)

Retrospective Data Show Potential Real-World TTNT and OS Improvements With Next-Generation BTK Inhibitors in R/R MCL
Retrospective data showed zanubrutinib was associated with improved real-world overall survival vs ibrutinib in second- or third-line mantle cell lymphoma.
onclive · 3mo ago

Data sources

openFDA · ClinicalTrials.gov · OpenTargets

last refreshed 30m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

CALQUENCE

🐶 often sniffed alongside

indications

targets

all catalysts(13)

Trials studying CALQUENCE

Patent cliff

patents (17)

FDA exclusivities (3)

News(1)

Report a data issue

comments(0)

CALQUENCE

🐶 often sniffed alongside

indications

targets

all catalysts(13)

Trials studying CALQUENCE

Patent cliff

patents (17)

FDA exclusivities (3)

News(1)

Report a data issue

comments(0)